Skip to Main Content

Paper Details

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.
Alzheimers Dement (N Y)
98
2018
AD, ADAD, Alzheimer's, Alzheimer's disease, Autosomal-Dominant Alzheimer's Disease, Autosomal-dominant Alzheimer's disease, E280A, PSEN1, PSEN1 E280A mutation, Participants, autosomal-dominant Alzheimer's disease, cognitive impairment, crenezumab, dementia, fluorodeoxyglucose, oligomers, p-tau, participants, tau
Author NameAffiliation
Pierre N TariotBanner Alzheimer's Institute
Ronald G ThomasUniversity of California San Diego School of Medicine
Lon S SchneiderUSC State of California Alzheimer's Disease Research and Clinical Center
Lee A Honigberg
Kewei ChenBanner Alzheimer's Institute
Eric M ReimanBanner Alzheimer's Institute
  • 1 - 6

Datasets

Release 1.2